Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS (EV06)

A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection

The primary objective of the proposed phase I trial is to evaluate the safety and tolerability of DNA-HIV-PT123 and AIDSVAX®B/E combination regimen. Though both DNA-HIV-PT123 and AIDSVAX®B/E and the combination of the two vaccines have been evaluated in humans and have shown to be safe and well tolerated, this is the first time the combination regimen is being evaluated in HIV-1 uninfected African populations with and without S. mansoni. The secondary objective of the trial is to evaluate the effect of S. mansoni infection on the immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX® B/E vaccine regimen. Successful vaccination against most viruses requires efficient Th1 response. There is evidence that helminth infections skew the host immune system of human and animals to T-helper type 2 (Th2) and induce immunosuppression. Therefore, there is a potential that helminth infected populations may not generate the desired immune responses to vaccines designed to drive Th1-type and cytotoxic T-cell responses.

Furthermore, the influence of helminth infections on the development of protective antibody responses remains unclear. Limited data in animal models suggests that worm infections reduced efficacy of vaccines.

The proposed vaccine trial will generate safety, tolerability and immunogenicity data of a vaccination regimen with simultaneous administration of a candidate HIV DNA vaccine (DNA-HIV-PT123) and a gp120 protein vaccine (AIDSVAX®B/E). This will be the first HIV vaccine trial to prospectively evaluate the impact of the S. mansoni infection on safety and immune responses to HIV vaccines.

Study Overview

• Status: Completed
• Conditions: HIV/AIDS
• Intervention / Treatment: Biological: DNA; Biological: AIDSVAX B/E

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 1

Contacts and Locations

Study Locations

• Uganda
  • Entebbe, Uganda
    • Uganda Virus Research Institute - International AIDS Vaccine Initiative HIV Vaccine Program (UVRI-IAVI)
  • Masaka, Uganda
    • Medical Research Council (MRC) /Uganda Virus Research Institute (UVRI)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. HIV-1 uninfected adults aged 18-45 years, as confirmed by a medical history, physical exam, and laboratory tests during screening
2. In 50% of study volunteers, positive for S. mansoni infection but negative for other helminth infections.
3. In 50% of study volunteers, negative for S. mansoni and other helminth infections
4. Willing to forgo treatment with praziquantel until after completion of week 26 visit in the trial.
5. Able and willing to provide written informed consent prior to screening
6. Aged 18 through 45 years on the day of first vaccination
7. Able and willing to complete screening (about 1 month) and available for the planned follow-up period (9months)
8. Willing to undergo HIV testing, risk reduction counselling, receive HIV test results and committed to maintaining low risk behaviour for the trial duration
9. If female of childbearing potential (not menopausal or sterilised), willing to use a non-barrier contraceptive method from screening through the end of the study. Acceptable contraceptive methods include hormonal contraceptives (injection, transdermal patch, or implant) and intrauterine device (IUD).
10. Willing to provide blood, urine and stool samples for laboratory examination

Exclusion Criteria:

1. HIV-1 infection
2. Infection with other helminths
3. Symptomatic and asymptomatic malaria infection (presence of malaria parasites on thick blood smear)
4. Treatment with praziquantel in the past 3 months
5. S. mansoni egg count of>2000 eggs per gram of stool
6. Clinically significant acute or chronic illness at the time of randomization.
7. Any clinically relevant abnormality on history or examination
8. Use of immunosuppressive medication (other than inhaled or topical immunosuppressants)
9. Receipt of immunoglobulin within past 60 days

10. Abnormal laboratory values as specified below from blood collected within 28 days prior to randomization:

    1. Hematology

       • Haemoglobin <9.0 g/dL or<5.59 mmol/L
       • Absolute Neutrophil Count (ANC): < 1000/mm3or < 1.0 x 109/L
       • Absolute Lymphocyte Count (ALC): ≤ 500/mm3or ≤ 0.5 x 109/L
       • Platelets: ≤ 90,000 ≥ 550,000/mm3or ≤ 90 x 109 ≥ 550 x 109/L

    2. Chemistry

       • Creatinine: > 1. 1 x ULN
       • AST: >2.6 x ULN
       • ALT: >2.6 x ULN

    3. Urinalysis: abnormal dipstick confirmed by microscopy

       • Protein 2+ or more
       • Blood 2+ or more (not due to menses)

11. Reported high-risk behaviour for HIV infection within 3 months prior to first vaccination, as defined by:

    • Unprotected sexual intercourse with a known HIV-infected person, a partner known to be at high risk of HIV infection or a casual partner
    • Unprotected sexual intercourse with more than one sexual partner
    • Engagement in sex work for money or drugs
    • Use of recreational drugs (e.g. marijuana) and/or weekly or more frequent alcohol use
    • Current or past STI
12. History or evidence of autoimmune disease.
13. Positive for Hepatitis B surface antigen (HbsAg), positive for antibodies to Hepatitis C virus (HCV) or active syphilis.
14. Receipt of blood or blood products within the previous 6 months
15. History of severe allergic reactions to any substance requiring hospitalization or emergency medical care (e.g. Steven-Johnson syndrome, bronchospasm or hypotension)
16. Prior or current participation in another investigational agent trial
17. Current anti-tuberculosis (TB) prophylaxis or therapy
18. If female, currently pregnant (positive serum or urine pregnancy test), planning to get pregnant in the next 9months or lactating
19. History or evidence of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may compromise the volunteer's safety or interfere with the evaluation of the safety or immunogenicity of the vaccine

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DNA and protein; 4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals	Biological: DNA; DNA co-administered with protein at month 0, 1 and 6; Other Names: DNA-HIV-PT123; Biological: AIDSVAX B/E; Protein co-administered with DNA at month 0,1 and 6
Active Comparator: Vaccination without S. mansoni infection; DNA Protein	Biological: DNA; DNA co-administered with protein at month 0, 1 and 6; Other Names: DNA-HIV-PT123; Biological: AIDSVAX B/E; Protein co-administered with DNA at month 0,1 and 6

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of volunteers with local and systemic reactogenicity events during a 7 day follow up period after each vaccination	7 days post each vaccination
Proportion of volunteers with adverse events during a 4 week follow up period after each vaccination	4 weeks post each vaccination
Proportion of volunteers with abnormal laboratory parameters during a 4 week follow up period after each vaccination	4 weeks post each vaccination
Proportion of volunteers with serious adverse events throughout the study period	Each participant will be followed for 9 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of volunteers with HIV-specific CD4+ and CD8+ T cell responses as assessed by IFN-g ELISpot and multiparameter flow cytometry (IFN-g TNF-a and IL-2) 2 weeks after the 2nd and 3rd vaccination	two weeks post 2nd and 3 vaccination
Magnitude of HIV-specific CD4+ and CD8+ T cell responses as assessed by IFN-g ELISpot and multiparameter flow cytometry (IFN-g TNF-a and IL-2) 2 weeks after the 2nd and 3rd vaccination	two weeks post 2nd and 3 vaccination
HIV-specific Env binding Antibody response 2 weeks after the 2nd and 3rd vaccination	two weeks post 2nd and 3 vaccination
Magnitude and breadth of neutralizing antibody responses against tier 1 and tier 2 HIV-1 isolates 2 weeks after the 2nd and 3rd vaccination	two weeks post 2nd and 3 vaccination

Collaborators and Investigators

• Sponsor: EuroVacc Foundation
• Collaborators: Medical Research Council; Centre Hospitalier Universitaire Vaudois; MRC/UVRI and LSHTM Uganda Research Unit; International AIDS Vaccine Initiative
• Investigators: Principal Investigator: Pontiano Kaleebu, Medical Research Council (MRC) / Uganda Virus Research Institute (UVRI)

Study record dates

Study Major Dates

• Study Start: September 1, 2014
• Primary Completion (Actual): January 1, 2016
• Study Completion (Actual): January 1, 2016

Study Registration Dates

• First Submitted: July 18, 2014
• First Submitted That Met QC Criteria: March 2, 2015
• First Posted (Estimate): March 3, 2015

Study Record Updates

• Last Update Posted (Estimate): January 22, 2016
• Last Update Submitted That Met QC Criteria: January 21, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: HIV/AIDS vaccine; helminth infection; Impact of co-infection
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome
• Other Study ID Numbers: EV06